Evidence digest
What the research on Epithalon actually shows
The indexed literature on Epithalon includes human clinical or observational records (1 human-clinical or observational record). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Epithalon is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 1 studies indexed · 1 human · compound record
- Studies indexed
- 1
- Human evidence
- 1
- Preclinical only
- 0
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for Epithalon (1).
- Published research is indexed back to 2000, with roughly 142 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether Epithalon is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosaNeuro endocrinology letters · 2002 | Human — controlled trial | Not recorded | — | We have studied the effect of tetrapeptide Epitalon (Ala-Glu-Asp-Gly) on the course of congenital pigmented degeneration of the retina. The application of Epitalon in Campbell rats is found to intensify the bioelectric and functional activity of the retina due to the preservation of its morphological structure. Epitalon therapy in patients with degenerative retinal lesions results in a positive clinical effect in 90% of the cases. The analysis of Epitalon effects suggests tha… | PMID 12195242 |
Vendors listing Epithalon
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Curo | 93.877% | 1 | profile → |
| Next Gen Peptides | 93.897% | 1 | profile → |
| PeptidePlugs | 89.790% | 3 | profile → |
| Hydro Research Peptides | 88.289% | 1 | profile → |
| Protide Health | 83.994% | 0 | profile → |
| American Peptides | 83.6100% | 1 | profile → |
| Origin Labs | 81.885% | 0 | profile → |
| Northline Labs | 79.493% | 0 | profile → |
| NeuroLabs Research | 79.386% | 0 | profile → |
| Koi Peptides | 79.394% | 1 | profile → |
| ZC Labs | 79.384% | 1 | profile → |
| Good Science Bio | 79.275% | 0 | profile → |
| Ascension Peptides | 78.186% | 0 | profile → |
| Licensed Peptides | 7789% | 1 | profile → |
| Simple Peptide | 7489% | 1 | profile → |
| True Research Labs | 71.971% | 0 | profile → |
| GenX Peptides | 70.868% | 0 | profile → |
| Vertex Labs | 70.170% | 1 | profile → |
| Improved Peptides | 7089% | 0 | profile → |
| Eternal Peptides | 68.265% | 0 | profile → |
| BioLongevity Labs | 67.274% | 0 | profile → |
| Evolve Peptides | 65.567% | 0 | profile → |
| Mile High Compounds | 65.494% | 0 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.